These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 22740425)

  • 1. Tritium-labeled brivaracetam with high specific activity: preparation, characterization and application in human brain samples.
    Hildenbrand S; Schoch S; von Lehe M; Surges R; Müller CE
    ChemMedChem; 2012 Aug; 7(8):1369-74. PubMed ID: 22740425
    [No Abstract]   [Full Text] [Related]  

  • 2. Brivaracetam UCB.
    Malawska B; Kulig K
    Curr Opin Investig Drugs; 2005 Jul; 6(7):740-6. PubMed ID: 16044671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.
    Gillard M; Fuks B; Leclercq K; Matagne A
    Eur J Pharmacol; 2011 Aug; 664(1-3):36-44. PubMed ID: 21575627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A New SV2A Ligand for Epilepsy.
    Rogawski MA
    Cell; 2016 Oct; 167(3):587. PubMed ID: 27768878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brivaracetam: First Global Approval.
    Markham A
    Drugs; 2016 Mar; 76(4):517-22. PubMed ID: 26899665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brivaracetam (Briviact) for epilepsy.
    Med Lett Drugs Ther; 2016 Jul; 58(1499):95-6. PubMed ID: 27403785
    [No Abstract]   [Full Text] [Related]  

  • 7. [Antiepileptic drugs].
    Herranz JL
    Rev Neurol; 2018 Jun; 66(s02):S21-S25. PubMed ID: 29876908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brivaracetam for epilepsy.
    Hellerslia V; Asistido JM; Iyamu A
    JAAPA; 2019 May; 32(5):21-22. PubMed ID: 31033711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy.
    Pollard JR
    Curr Opin Investig Drugs; 2008 Jan; 9(1):101-7. PubMed ID: 18183537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of Approved Drugs with Synaptic Vesicle Protein 2A.
    Danish A; Namasivayam V; Schiedel AC; Müller CE
    Arch Pharm (Weinheim); 2017 Apr; 350(3-4):. PubMed ID: 28220535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate.
    Perucca E
    Epilepsia; 2009 Dec; 50 Suppl 12():49-50. PubMed ID: 19941524
    [No Abstract]   [Full Text] [Related]  

  • 12. 3,3-Dialkyl- and 3-alkyl-3-benzyl-substituted 2-pyrrolidinones: a new class of anticonvulsant agents.
    Reddy PA; Hsiang BC; Latifi TN; Hill MW; Woodward KE; Rothman SM; Ferrendelli JA; Covey DF
    J Med Chem; 1996 Apr; 39(9):1898-906. PubMed ID: 8627613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brivaracetam for the treatment of epilepsy in adults.
    Mula M
    Expert Rev Neurother; 2014 Apr; 14(4):361-5. PubMed ID: 24625006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new class of pyrrolidin-2-ones: synthesis and pharmacological study.
    Saturnino C; Capasso A; Saturnino P; De Martino G; Sorrentino L; Lancelot JC; Robba M
    J Pharm Belg; 1997; 52(2):57-60. PubMed ID: 9193130
    [No Abstract]   [Full Text] [Related]  

  • 15. Physiologically based pharmacokinetic/pharmacodynamic animal-to-man prediction of therapeutic dose in a model of epilepsy.
    Brochot A; Zamacona M; Stockis A
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):256-62. PubMed ID: 20102365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of indolone acetamides as novel SV2A ligands with improved potency toward seizure suppression.
    Frycia A; Starck JP; Jadot S; Lallemand B; Leclercq K; Lo Brutto P; Matagne A; Verbois V; Mercier J; Kenda B
    ChemMedChem; 2010 Feb; 5(2):200-5. PubMed ID: 20039359
    [No Abstract]   [Full Text] [Related]  

  • 17. Characterization and pharmacology of the GHB receptor.
    Ticku MK; Mehta AK
    Ann N Y Acad Sci; 2008 Oct; 1139():374-85. PubMed ID: 18991884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous-flow protocol for the synthesis of enantiomerically pure intermediates of anti epilepsy and anti tuberculosis active pharmaceutical ingredients.
    Aguiar RM; Leão RAC; Mata A; Cantillo D; Kappe CO; Miranda LSM; de Souza ROMA
    Org Biomol Chem; 2019 Feb; 17(6):1552-1557. PubMed ID: 30693360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.
    Jiang W; Tucci FC; Tran JA; Fleck BA; Wen J; Markison S; Marinkovic D; Chen CW; Arellano M; Hoare SR; Johns M; Foster AC; Saunders J; Chen C
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5610-3. PubMed ID: 17822895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crossreactivity in antiepileptic drug monitoring: Reply to: Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy-a monocenter survey.
    Strasser B; Tomasits J
    Seizure; 2022 Jan; 94():115-116. PubMed ID: 34894439
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.